信用评级机构穆迪将丹麦制药巨头诺和诺德的长期信用评级从A1上调至Aa3，展望从“稳定”上调至“正面”。

　　穆迪表示，此次评级上调反映了该公司在糖尿病和肥胖药物（主要是Ozempic和Wegovy）方面的增长，以及未来三年适度的专利风险，以及坚实且日益多样化的产品线，尽管重点是糖尿病和肥胖治疗。该机构补充说，诺和诺德非常强劲的信贷指标也发挥了作用。

　　上调展望是由于穆迪预计诺和诺德将在未来12至18个月内继续保持稳健的运营表现，同时将调整后的总债务与EBITDA比率维持在1.0倍以下。

海量资讯、精准解读，尽在新浪财经APP

责任编辑：于健 SF069

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.